Armistice Capital’s Agios Pharmaceuticals AGIO Stock Holding History

Armistice Capital’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$91.9M	Sell	2,716,000 -320,000	-11%	-$9.07M	1.63%	10
2025 Q4	$82.6M	Buy	3,036,000 +2,272,000	+297%	+$79.7M	0.98%	13
2025 Q3	$30.7M	Sell	764,000 -404,000	-35%	-$15.2M	0.45%	31
2025 Q2	$38.8M	Sell	1,168,000 -880,000	-43%	-$26.7M	0.67%	22
2025 Q1	$60M	Sell	2,048,000 -216,304	-10%	-$7.18M	0.9%	14
2024 Q4	$74.4M	Buy	2,264,304 +57,234	+3%	+$2.69M	1.02%	18
2024 Q3	$98.1M	Buy	2,207,070 +127,919	+6%	+$5.81M	1.57%	10
2024 Q2	$89.7M	Sell	2,079,151 -884,849	-30%	-$31.9M	1.13%	9
2024 Q1	$86.7M	Sell	2,964,000 -560,000	-16%	-$15M	1.15%	10
2023 Q4	$78.5M	Buy	3,524,000 +200,000	+6%	+$4.48M	1.07%	12
2023 Q3	$82.3M	Buy	3,324,000 +68,000	+2%	+$1.8M	1.26%	7
2023 Q2	$92.2M	Sell	3,256,000 -204,000	-6%	-$5.08M	1.33%	9
2023 Q1	$79.5M	Buy	3,460,000 +710,000	+26%	+$18.9M	1.14%	18
2022 Q4	$77.2M	Buy	2,750,000 +826,000	+43%	+$23.3M	1.35%	17
2022 Q3	$54.4M	Buy	+1,924,000	New	+$51.6M	0.94%	27

Other funds holding AGIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Armistice Capital's AGIO Position: Q1 2026 in Review

Armistice Capital reduced its Agios Pharmaceuticals (AGIO) stake by 11% in Q1 2026, selling an estimated $9.07M and leaving 2,716,000 shares worth $91.9M. The position accounts for 1.63% of the portfolio, ranked #10.

Armistice Capital first reported a position in AGIO in Q3 2022 and has held it in 15 quarters since. The position peaked at $98.1M in Q3 2024. 232 funds tracked by Wall St. Rank hold AGIO as of Q1 2026.

Armistice Capital held 2,716,000 shares of Agios Pharmaceuticals worth $91.9M as of Q1 2026.
Armistice Capital sold 320,000 Agios Pharmaceuticals shares in Q1 2026, an estimated $9.07M.
Agios Pharmaceuticals made up 1.63% of Armistice Capital's portfolio in Q1 2026, its #10 holding.
Armistice Capital first reported a position in Agios Pharmaceuticals in Q3 2022 and has held it in 15 quarters since.
Armistice Capital's Agios Pharmaceuticals position peaked at $98.1M in Q3 2024.
232 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2026.

Based on Armistice Capital's 13F filing for Q1 2026, filed 15 May 2026.